Authors: Christian Ovesen
Institution: Bispebjerg Hospital, Copenhagen University
This week, I had the pleasure of attending the 10th World Intracranial Hemorrhage Conference in the beautiful city of Barcelona, Spain. It was a privilege to meet so many eminent colleagues and learn from their invaluable insights and expertise. The meeting featured an excellent scientific program covering a wide range of topics in intracranial haemorrhage, with a particular focus on the surgical management of intracerebral haemorrhage. The conference provided a unique opportunity to discuss emerging evidence and strengthen collaborations within this field.
The meeting opened with a session dedicated to the management of chronic subdural hematomas (cSDH). Evidence from the EMBOLISE [1], EMMA-CAN [2], and STEM [3] trials is converging to support the efficacy of middle meningeal artery (MMA) embolisation in reducing the risk of cSDH recurrence. In contrast, the MAGIC-MT [4] and EMPROTECT [5] trials reported neutral findings. In the EMPROTECT trial, the neutral findings may, at least in part, be explained by differences in the embolisation procedure (using particles versus liquid embolic agents) relative to the protocols employed in the three trials that demonstrated a positive treatment effect. Future studies should focus on identifying the optimal embolisation technique, determining the most effective timing of the procedure, and refining patient selection criteria. Finally, a new promising endovascular approach to subdural hematoma evacuation was briefly highlighted, raising the possibility that MMA embolisation could be combined with direct endovascular drainage of the chronic subdural hematoma.
A substantial portion of the meeting focused on the emerging evidence for hematoma evacuation in patients with acute intracerebral haemorrhage. The three landmark trials, ENRICH, MIND, and MISTIE III, are collectively shaping our understanding of the potential benefits of hematoma evacuation, while also helping to identify the patient subgroups most likely to derive benefit from these interventions.
MISTIE III (2019) [6]: The MISTIE III trial enrolled patients with supratentorial spontaneous acute intracerebral haemorrhage, a hematoma volume >30 mL, an NIHSS score >6, and little or no pre-stroke disability. In addition, the hematoma was required to be radiologically stable for at least 6 hours prior to randomisation. Participants were randomised to the MISTIE procedure plus best medical therapy or to best medical therapy alone. The MISTIE procedure involved stereotactic placement of a rigid cannula into the hematoma, followed by aspiration of as much clot as possible. A drainage catheter was then left within the hematoma cavity, through which alteplase was administered to facilitate further clot dissolution and evacuation.
A total of 19,942 patients were screened for eligibility, and 506 participants were randomised. Overall, surgical treatment was not associated with a significantly higher probability of achieving a favourable functional outcome (mRS 0-3) at 1 year compared with best medical therapy (risk difference 4%, 95% CI −4% to 12%). Furthermore, no evidence of heterogeneity in treatment effect was observed according to hematoma location, with similar results in patients with deep (basal ganglia) and lobar haemorrhages. Although the primary endpoint was not met, subsequent analyses suggested that achieving substantial hematoma reduction may be an important determinant of functional outcome, highlighting the importance of procedural efficacy in future studies.
ENRICH (2024) [7]: The ENRICH trial enrolled patients with supratentorial spontaneous acute intracerebral haemorrhage, a hematoma volume of 30 to 80 mL, a National Institutes of Health Stroke Scale (NIHSS) score >5, and little or no pre-stroke disability. Participants were eligible only if surgery could be initiated within 24 hours of symptom onset. Patients were randomised to minimally invasive trans-sulcal parafascicular surgery plus best medical management or to best medical management alone. The primary outcome was utility-weighted modified Rankin Scale (UW-mRS) score at 180 days.
Of the 11,603 patients screened, 300 were randomised. The primary analysis demonstrated heterogeneity of treatment effect according to hematoma location. Among patients with anterior basal ganglia haemorrhages, surgery was not associated with a more favourable UW-mRS score at 180 days (mean difference −0.013, 95% credible interval −0.147 to 0.116). In contrast, among patients with lobar haemorrhages, surgery was associated with improved functional outcomes, with a higher UW-mRS score at 180 days (MD 0.127, 95% Cr 0.035 to 0.219). These findings show a benefit of minimally invasive hematoma evacuation in carefully selected patients with lobar intracerebral haemorrhage but could not show a treatment benefit in patients with anterior basal ganglia haemorrhages.
MIND (2025) [8]: The MIND trial enrolled patients with supratentorial spontaneous acute intracerebral haemorrhage, a hematoma volume between 20 and 80 mL, an NIHSS score >5, and little or no pre-stroke disability. Participants were eligible if baseline imaging could be performed within 24 hours of symptom onset. Patients were randomised in a 2:1 ratio to either minimally invasive surgery plus best medical management or best medical management alone. Those assigned to the surgical arm underwent endoscopic hematoma evacuation within 72 hours of symptom onset. During the trial, 4,066 patients were screened for eligibility, and 236 participants were randomised. Following publication of the ENRICH trial in 2023, enrolment of patients with lobar haemorrhage was halted because of a perceived loss of clinical equipoise. The trial subsequently continued to enrol only patients with deep intracerebral haemorrhage, but was ultimately terminated early for futility.
The primary outcome, ordinal modified Rankin Scale (mRS) score at 180 days, showed no significant benefit of minimally invasive surgery compared to best medical management (odds ratio 1.03, 95% CI 0.62 to 1.72). Exploratory analyses stratified by hematoma location similarly failed to demonstrate evidence of heterogeneity in treatment effect, with no clear difference in treatment response between patients with lobar and deep haemorrhages.
The heterogeneous findings of these trials are beginning to illuminate the factors that are likely to be crucial in determining the effectiveness of surgical treatment for intracerebral haemorrhage. One key consideration appears to be the timing of the intervention, as patients in ENRICH generally underwent surgery considerably earlier than those enrolled in MISTIE III and MIND. In addition, it remains uncertain, whether patients with deep supratentorial hematomas derive the same benefit from surgical evacuation as those with lobar haemorrhages. Future studies will be essential to establish the efficacy of surgical evacuation, determine whether treatment effects vary according to hematoma location, the optimal timing of the intervention, and identify the most effective minimally invasive surgical techniques for hematoma evacuation. Results from several ongoing trials, including REACH (NCT07651631), MINUTE (NCT07260916), EVACUATE (NCT04434807), EMINENT-ICH (NCT05681988), and DIST (NCT05460793), are eagerly awaited.
References:
- Davies JM, Knopman J, Mokin M, Hassan AE, Harbaugh RE, Khalessi A, et al. Adjunctive Middle Meningeal Artery Embolization for Subdural Hematoma. N Engl J Med. 2024;391:1890-900.
- Shankar JJS, Alcock S, Kashani N, Darsaut T, Wang BH, Dos Santos MP, et al. Management of Chronic Subdural Hematoma With Adjunctive Embolization of Middle Meningeal Artery: The EMMA-Can Randomized Clinical Trial. JAMA. 2026;335:1787-95.
- Fiorella D, Monteith SJ, Hanel R, Atchie B, Boo S, McTaggart RA, et al. Embolization of the Middle Meningeal Artery for Chronic Subdural Hematoma. N Engl J Med. 2025;392:855-64.
- Liu J, Ni W, Zuo Q, Yang H, Peng Y, Lin Z, et al. Middle Meningeal Artery Embolization for Nonacute Subdural Hematoma. N Engl J Med. 2024;391:1901-12.
- Shotar E, Mathon B, Salle H, Rouchaud A, Mounayer C, Bricout N, et al. Meningeal Embolization for Preventing Chronic Subdural Hematoma Recurrence After Surgery: The EMPROTECT Randomized Clinical Trial. JAMA. 2025;334:127-35.
- Hanley DF, Thompson RE, Rosenblum M, Yenokyan G, Lane K, McBee N, et al. Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial. Lancet. 2019;393:1021-32.
- Pradilla G, Ratcliff JJ, Hall AJ, Saville BR, Allen JW, Paulon G, et al. Trial of Early Minimally Invasive Removal of Intracerebral Hemorrhage. N Engl J Med. 2024;390:1277-89.
- Arthur AS, Jahromi BS, Saphier PS, Nickele CM, Ryan RW, Vajkoczy P, et al. Minimally Invasive Surgery vs Medical Management Alone for Intracerebral Hemorrhage: The MIND Randomized Clinical Trial. JAMA Neurol. 2025;82:1113-21.
ESOC is Europe’s leading forum for advances in research and clinical care of patients with cerebrovascular diseases. ESOC 2027 will live up to its expectation, and present to you a packed, high quality scientific programme including major clinical trials, state-of-the-art seminars, educational workshops, scientific communications of the latest research, and debates about current controversies. Learn more.

